Chronic nicotine restores normal Aβ levels and prevents short-term memory and E-LTP impairment in Aβ rat model of Alzheimer's disease

Neurobiology of Aging

Volumn 32, Issue 5, 2011, Pages 834-844

  Srivareerat, Marisa ^a   Tran, Trinh T ^a   Salim, Samina ^a   Aleisa, Abdulaziz M ^b   Alkadhi, Karim A ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

7 nAChR; A ; BACE1; BDNF; LTP; Osmotic pump

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; BRAIN DERIVED NEUROTROPHIC FACTOR; BUNGAROTOXIN RECEPTOR; NICOTINE; NICOTINIC RECEPTOR ALPHA4;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; EARLY PHASE LONG TERM POTENTIATION; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPAL CA1 REGION; LEARNING; LEARNING DISORDER; LONG TERM POTENTIATION; MALE; MAZE TEST; MEMORY DISORDER; NONHUMAN; PRIORITY JOURNAL; RAT; SHORT TERM MEMORY; SPATIAL LEARNING; SYNAPTIC TRANSMISSION; UPREGULATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CA1 REGION, HIPPOCAMPAL; DISEASE MODELS, ANIMAL; GANGLIONIC STIMULANTS; LEARNING; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MEMORY DISORDERS; MEMORY, SHORT-TERM; NICOTINE; RATS; RATS, WISTAR; RECEPTORS, NICOTINIC; SYNAPTIC TRANSMISSION; UP-REGULATION;

EID: 79954594758     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.04.015     Document Type: Article

References (81)

1. Aleisa A.M., Alzoubi K.H., Alkadhi K.A. Nicotine prevents stress-induced enhancement of long-term depression in hippocampal area CA1: electrophysiological and molecular studies. J. Neurosci. Res. 2006, 83:309-317.
2. Aleisa A.M., Alzoubi K.H., Gerges N.Z., Alkadhi K.A. Nicotine blocks stress-induced impairment of spatial memory and long-term potentiation of the hippocampal CA1 region. Int. J. Neuropsychopharmacol. 2006, 9:417-426.
3. Aleisa A.M., Alzoubi K.H., Gerges N.Z., Alkadhi K.A. Chronic psychosocial stress-induced impairment of hippocampal LTP: possible role of BDNF. Neurobiol. Dis. 2006, 22:453-462.
4. Alzoubi K.H., Aleisa A.M., Gerges N.Z., Alkadhi K.A. Nicotine reverses hypothyroidism-induced impairment of learning and memory: behavioral and electrophysiological studies. J. Neurosci. Res. 2006, 84(5):944-953.
5. Barde Y.A. Trophic factors and neuronal survival. Neuron 1989, 2:1525-1534.
6. Blanquet P.R., Lamour Y. Brain-derived neurotrophic factor increases Ca2+/calmodulin-dependent protein kinase 2 activity in hippocampus. J. Biol. Chem. 1997, 272(39 (September 26)):24133-24136.
7. Benwell M.E., Balfour D.J., Anderson J.M. Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J. Neurochem. 1988, 50:1243-1247.
8. Bourne K.Z., Ferrari D.C., Lange-Dohna C., Rossner S., Wood T.G., Perez-Polo J.R. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J. Neurosci. Res. 2007, 85(6 (May 1)):1194-1204.
9. Chen L., Yamada K., Nabeshima T., Sokabe M. Alpha7 nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. Neuropharmacology 2006, 50:254-268.
10. Costa G., Abin-Carriquiry J.A., Dajas F. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res. 2001, 888:336-342.
11. Diamond D.M., Park C.R., Heman K.L., Rose G.M. Exposing rats to a predator impairs spatial working memory in the radial arm water maze. Hippocampus 1999, 9:542-552.
12. Dickerson T.J., Janda K.D. Glycation of the amyloid beta-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:8182-8187.
13. Dineley K.T., Westerman M., Bui D., Bell K., Ashe K.H., Sweatt J.D. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. J. Neurosci. 2001, 21:4125-4133.
14. Dineley K.T. Beta-amyloid peptide-nicotinic acetylcholine receptor interaction: the two faces of health and disease. Front. Biosci. 2007, 12 (September 1):5030-5038.
15. Dougherty J.J., Wu J., Nichols R.A. Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J. Neurosci. 2003, 23:6740-6747.
16. Dunne M.P., Macdonald D., Hartley L.R. The effects of nicotine upon memory and problem solving performance. Physiol. Behav. 1986, 37:849-854.
17. Freir D.B., Holscher C., Herron C.E. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J. Neurophysiol. 2001, 85:708-713.
18. Freir D.B., Herron C.E. Nicotine enhances the depressive actions of A beta 1-40 on long-term potentiation in the rat hippocampal CA1 region in vivo. J. Neurophysiol. 2003, 89(6):2917-2922.
19. Fujii S., Ji Z., Morita N., Sumikawa K. Acute and chronic nicotine exposure differentially facilitate the induction of LTP. Brain Res. 1999, 846:137-143.
20. Garrido R., Malecki A., Hennig B., Toborek M. Nicotine attenuates arachidonic acid-induced neurotoxicity in cultured spinal cord neurons. Brain Res. 2000, 861:59-68.
21. Garrido R., Mattson M.P., Hennig B., Toborek M. Nicotine protects against arachidonic acid-induced caspase activation, cytochrome c release and apoptosis of cultured spinal cord neurons. J. Neurochem. 2001, 76:1395-1403.
22. Hartlage-Rübsamen M., Zeitschel U., Apelt J., Gärtner U., Franke H., Stahl T., Günther A., Schliebs R., Penkowa M., Bigl V., Rossner S. Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. Glia 2003, 41(2 (January 15)):169-179.
23. Hellstrom-Lindahl E., Mousavi M., Zhang X., Ravid R., Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res. Mol. Brain Res. 1999, 66:94-103.
24. Hellstrom-Lindahl E., Court J., Keverne J., Svedberg M., Lee M., Marutle A., Thomas A., Perry E., Bednar I., Nordberg A. Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur. J. Neurosci. 2004, 19:2703-2710.
25. Hock C., Heese K., Muller-Spahn F., Hulette C., Rosenberg C., Otten U. Decreased TrkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease. Neurosci. Lett. 1998, 241:151-154.
26. Holsinger R.M., McLean C.A., Beyreuther K., Masters C.L., Evin G. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann. Neurol. 2002, 51(6 (June)):783-786.
27. Itoh A., Akaike T., Sokabe M., Nitta A., Iida R., Olariu A., Yamada K., Nabeshima T. Impairments of long-term potentiation in hippocampal slices of beta-amyloid-infused rats. Eur. J. Pharmacol. 1999, 382(3):167-175.
28. Jonnala R.R., Buccafusco J.J. Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists. J. Neurosci. Res. 2001, 66:565-572.
29. Kaneko S., Maeda T., Kume T., Kochiyama H., Akaike A., Shimohama S., Kimura J. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha7-neuronal receptors and neuronal CNS receptors. Brain Res. 1997, 765:135-140.
30. Kang J.E., Cirrito J.R., Dong H., Csernansky J.G., Holtzman D.M. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:10673-10678.
31. Kasa P., Rakonczay Z., Gulya K. The cholinergic system in Alzheimer's disease. Prog. Neurobiol. 1997, 52:511-535.
32. Kenny P.J., File S.E., Rattray M. Acute nicotine decreases, and chronic nicotine increases the expression of brain-derived neurotrophic factor mRNA in rat hippocampus. Brain Res. Mol. Brain Res. 2000, 85:234-238.
33. Klann E., Thiels E. Modulation of protein kinases and protein phosphatases by reactive oxygen species: implications for hippocampal synaptic plasticity. Prog. Neuropsychopharmacol. Biol. Psychiatry 1999, 23:359-376.
34. Lahiri D.K., Utsuki T., Chen D., Farlow M.R., Shoaib M., Ingram D.K., Greig N.H. Nicotine reduces the secretion of Alzheimer's beta-amyloid precursor protein containing beta-amyloid peptide in the rat without altering synaptic proteins. Ann. N. Y. Acad. Sci. 2002, 965:364-372.
35. Lee P.N. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994, 13:131-144.
36. Le Foll B., Diaz J., Sokoloff P. A single cocaine exposure increases BDNF and D3 receptor expression: implications for drug-conditioning. Neuroreport 2005, 16(2 (February 8)):175-178.
37. Levin E.D., Wilson W., Rose J.E., McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996, 15:429-436.
38. Levin E.D., Castonguay M., Ellison G.D. Effects of the nicotinic receptor blocker mecamylamine on radial-arm maze performance in rats. Behav. Neural Biol. 1987, 48:206-212.
39. Linert W., Bridge M.H., Huber M., Bjugstad K.B., Grossman S., Arendash G.W. In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's diseases. Biochim. Biophys. Acta 1999, 1454:143-152.
40. Liu J., Fukunaga K., Yamamoto H., Nishi K., Miyamoto E. Differential roles of Ca(2+)/calmodulin-dependent protein kinase II and mitogen-activated protein kinase activation in hippocampal long-term potentiation. J. Neurosci. 1999, 19(19 (October 1)):8292-8299.
41. Liu Q., Zhao B. Nicotine attenuates beta-amyloid peptide-induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures. Br. J. Pharmacol. 2004, 141:746-754.
42. Liu Q., Wu J. Neuronal nicotinic acetylcholinere ceptors serve as sensitive targets that mediate beta-amyloid neurotoxicity. Acta Pharmacol. Sinica 2006, 27(10):1277-1286.
43. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
44. McGehee D.S., Heath M.J., Gelber S., Devay P., Role L.W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 1995, 269:1692-1696.
45. Miklossy J. Chronic inflammation and amyloidogenesis in Alzheimer's disease-role of Spirochetes. J. Alzheimer's Dis. 2008, 13(4 (May)):381-391.
46. Minichiello L., Calella A.M., Medina D.L., Bonhoeffer T., Klein R., Korte M. Mechanism of TrkB-mediated hippocampal long-term potentiation. Neuron 2002, 36:121-137.
47. Moore S.A., Huckerby T.N., Gibson G.L., Fullwood N.J., Turnbull S., Tabner B.J., El-Agnaf O.M., Allsop D. Both the d-(+) and l-(-) enantiomers of nicotine inhibit Abeta aggregation and cytotoxicity. Biochemistry 2004, 43:819-826.
48. Newhouse P.A., Potter A., Levin E.D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging 1997, 11:206-228.
49. Newhouse P.A., Potter A., Kelton M., Corwin J. Nicotinic treatment of Alzheimer's disease. Biol. Psychiatry 2001, 49:268-278.
50. Nordberg A., Winblad B. Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 1986, 72:115-119.
51. Parrott A.C., Winder G. Nicotine chewing gum (2mg, 4mg) and cigarette smoking: comparative effects upon vigilance and heart rate. Psychopharmacology (Berl.) 1989, 97:257-261.
52. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, San Diego, CA, USA. 2nd ed.
53. Peng X., Gerzanich V., Anand R., Whiting P.J., Lindstrom J. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol. Pharmacol. 1994, 46:523-530.
54. Perry E., Martin-Ruiz C., Lee M., Griffiths M., Johnson M., Piggott M., Haroutunian V., Buxbaum J.D., Nasland J., Davis K., Gotti C., Clementi F., Tzartos S., Cohen O., Soreq H., Jaros E., Perry R., Ballard C., McKeith I., Court J. Nicotinic receptor subtypes in human brain ageing Alzheimer and Lewy body diseases. Eur. J. Pharmacol. 2000, 393:215-222.
55. Quik M., Philie J., Choremis J. Modulation of alpha7 nicotinic receptor-mediated calcium influx by nicotinic agonists. Mol. Pharmacol. 1997, 51:499-506.
56. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 2004, 27:561-568.
57. Rezvani A.H., Levin E.D. Cognitive effects of nicotine. Biol. Psychiatry 2001, 49:258-267.
58. Ryan R.E., Ross S.A., Drago J., Loiacono R.E. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br. J. Pharmacol. 2001, 132:1650-1656.
59. Salomon A.R., Marcinowski K.J., Friedland R.P., Zagorski M.G. Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry 1996, 35:13568-13578.
60. Seguela P., Wadiche J., Dineley-Miller K., Dani J.A., Patrick J.W. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J. Neurosci. 1993, 13:596-604.
61. Shimohama S., Kihara T. Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity. Biol. Psychiatry 2001, 49:233-239.
62. Shimohama S., Greenwald D.L., Shafron D.H., Akaika A., Maeda T., Kaneko S., Kimura J., Simpkins C.E., Day A.L., Meyer E.M. Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res. 1998, 779:359-363.
63. Soto-Otero R., Méndez-Alvarez E., Hermida-Ameijeiras A., López-Real A.M., Labandeira-García J.L. Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease. Biochem. Pharmacol. 2002, 64:125-135.
64. Srivareerat M, Tran TT, Alzoubi, KH, Alkadhi, KA, 2008. Chronic psychosocial stress exacerbates impairment of cognition and LTP in a Aβ rat model of Alzheimer's disease Biol. Psychiatry (Epub ahead of print).
65. Sze C.I., Troncoso J.C., Kawas C., Mouton P., Price D.L., Martin L.J. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J. Neuropathol. Exp. Neurol. 1997, 56:933-944.
66. Tang Y., Yamada K., Kanou Y., Miyazaki T., Xiong X., Kambe F., Murata Y., Seo H., Nabeshima T. Spatiotemporal expression of BDNF in the hippocampus induced by the continuous intracerebroventricular infusion of beta-amyloid in rats. Brain Res. Mol. Brain Res. 2000, 80(2 (September 15)):188-197.
67. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
68. Tominaga A., Sugawara H., Inoue K., Miyata A. Implication of pituitary adenylate cyclase-activating polypeptide (PACAP) for neuroprotection of nicotinic acetylcholine receptor signaling in PC12 cells. J. Mol. Neurosci. 2008, 36:73-78.
69. Utsuki T., Shoaib M., Holloway H.W., Ingram D.K., Wallace W.C., Haroutunian V., Sambamurti K., Lahiri D.K., Greig N.H. Nicotine lowers the secretion of the Alzheimer's amyloid beta-protein precursor that contains amyloid beta-peptide in rat. J. Alzheimer's Dis. 2002, 4:405-415.
70. Vallejo Y.F., Buisson B., Bertrand D., Green W.N. Chronic nicotine exposure upregulates nicotinic receptors by a novel mechanism. J. Neurosci. 2005, 25:5563-5572.
71. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
72. Wang H.Y., Lee D.H., Davis C.B., Shank R.P. Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J. Neurochem. 2000, 75:1155-1161.
73. Wang H.Y., Lee D.H., D'Andrea M.R., Peterson P.A., Shank R.P., Reitz A.B. Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity implications for Alzheimer's disease pathology. J. Biol. Chem. 2000, 275:5626-5632.
74. Welsby P.J., Rowan M.J., Anwyl R. Beta-amyloid blocks high frequency stimulation induced LTP but not nicotine enhanced LTP. Neuropharmacology 2007, 53:188-195.
75. Whitehouse P.J., Martino A.M., Antuono P.G., Lowenstein P.R., Coyle J.T., Price D.L., Kellar K.J. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 1986, 371:146-151.
76. White H.K., Levin E.D. Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology (Berl.) 2004, 171:465-471.
77. White H.K., Levin E.D. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology (Berl.) 1999, 143:158-165.
78. Wilson A.L., Langley L.K., Monley J., Bauer T., Rottunda S., McFalls E., Kovera C., McCarten J.R. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol. Biochem. Behav. 1995, 51:509-514.
79. Wonnacott S. The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol. Sci. 1990, 11:216-219.
80. Yamagata T., Satoh T., Ishikawa Y., Nakatani A., Yamada M., Ikeuchi T., Hatanaka H. Brain-derived neurotropic factor prevents superoxide anion-induced death of PC12h cells stably expressing TrkB receptor via modulation of reactive oxygen species. Neurosci. Res. 1999, 35(1 (October)):9-17.
81. Zeng H., Zhang Y., Peng L., Shao H., Menon N.K., Yang J., Salomon A.R., Freidland R.P., Zagorski M.G. Nicotine and amyloid formation. Biol. Psychiatry 2001, 49:248-257.